P943: OUTCOME ANALYSIS BY CYTOGENETIC RISK GROUP AFTER RANDOMIZATION TO KRD OR KTD FOLLOWED BY K MAINTENANCE OR CONTROL IN PATIENTS WITH NTE NDMM (AGMT MM-02)

• Heinz Ludwig,
• Thomas Melchardt,
• Siegfried Sormann,
• Martin Schreder,
• Johannes Andel,
• Bernd Hartmann,
• Christoph Tinchon,
• Niklas Zojer,
• Eberhard Gunsilius,
• Klaus Podar,
• Alexander Egle,
• Wolfgang Willenbacher,
• Ewald Woell,
• Reinhard Ruckser,
• Boris Bozic,
• Maria Theresa Krauth,
• Andreas Petzer,
• Clemens A. Schmitt,
• Sigrid Machherndl-Spandl,
• Hermine Agis,
• Michael Fillitz,
• Song-Yau Wang,
• Stefan Knop,
• Bruno Paiva,
• Richard Greil

Affiliations

Heinz Ludwig

1 Wilhelminen Cancer Research Institute, c/o Department of Medicine I, Klinik Ottakring, Vienna, Austria

Thomas Melchardt

2 Paracelsus Medical University, Cancer Cluster Salzburg, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria

Siegfried Sormann

3 University Clinic for Internal Medicine, Department of Hematology, Graz, Austria

Martin Schreder

4 Klinik Ottakring, Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Vienna, Austria

Johannes Andel

5 LKH Steyr, Department of Internal Medicine II, Steyr, Austria

Bernd Hartmann

6 LKH Rankweil, Department of Internal Medicine II, Rankweil, Austria

Christoph Tinchon

7 LKH Hochsteiermark, Department of Internal Medicine, Leoben, Austria

Niklas Zojer

4 Klinik Ottakring, Department of Medicine I, Center for Oncology, Hematology, and Palliative Care, Vienna, Austria

Eberhard Gunsilius

8 Medical University Innsbruck, Department of Internal Medicine V, Innsbruck, Austria

Klaus Podar

9 University Clinic Krems, Department of Internal Medicine 2, Krems, Austria

Alexander Egle

2 Paracelsus Medical University, Cancer Cluster Salzburg, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria

Wolfgang Willenbacher

8 Medical University Innsbruck, Department of Internal Medicine V, Innsbruck, Austria

Ewald Woell

11 KH Zams, Department of Internal Medicine, Zams, Austria

Reinhard Ruckser

12 Klinik Donaustadt, Department of Medicine II, Vienna, Austria

Boris Bozic

12 Klinik Donaustadt, Department of Medicine II, Vienna, Austria

Maria Theresa Krauth

13 Medical University Vienna, University Clinic for Internal Medicine I, Division Hematology & Hemostaseology, Vienna, Austria

Andreas Petzer

14 Barmherzige Schwestern Linz, Department of Internal Medicine I, Linz, Austria

Clemens A. Schmitt

15 Kepler University Clinic Linz, Clinic for Internal Medicine 3, Linz, Austria

Sigrid Machherndl-Spandl

16 Ordensklinikum Linz Elisabethinen, Linz, Austria

Hermine Agis

17 Medical University Vienna, Department of Internal Medicine I, Division of Oncology, Vienna, Austria

Michael Fillitz

18 Hanusch Krankenhaus, Department of Internal Medicine, Vienna, Austria

Song-Yau Wang

19 University Clinic Leipzig, Medical Clinic and Policlinic I, Leipzig, Germany

Stefan Knop

20 Klinikum Nürnberg Nord, Clinic for Internal Medicine 5, Nürnberg, Germany

Bruno Paiva

21 Clinica Universidad de Navarra, Pamplona, Spain

Richard Greil

2 Paracelsus Medical University, Cancer Cluster Salzburg, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria